LIVZON PHARMACEUTICAL GROUP INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.98 CNY | -1.32% |
|
+2.99% | +11.34% |
| Sales 2024 * | 13.31B 1.84B 147B | Sales 2025 * | 14.47B 2B 160B | Capitalization | 31.44B 4.34B 348B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.16B 299M 23.92B | Net income 2025 * | 2.44B 337M 27B | EV / Sales 2024 * | 1.86 x |
| Net cash position 2024 * | 6.66B 919M 73.6B | Net cash position 2025 * | 5.85B 808M 64.69B | EV / Sales 2025 * | 1.77 x |
| P/E ratio 2024 * |
16.7
x | P/E ratio 2025 * |
14.7
x | Employees | 8,933 |
| Yield 2024 * |
4.14% | Yield 2025 * |
4.72% | Free-Float | 38.32% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.32% | ||
| 1 week | +2.99% | ||
| Current month | +6.79% | ||
| 1 month | +3.73% | ||
| 3 months | +11.72% | ||
| 6 months | +13.74% | ||
| Current year | +11.34% |
1 week
36.46
39.61
1 month
35.3139.61
Current year
32.7039.93
1 year
31.7240.58
3 years
28.8857.50
5 years
22.1562.20
10 years
14.0862.20
| Managers | Title | Age | Since |
|---|---|---|---|
Yang Gang Tang
PSD | President | 55 | 16/07/18 |
Yan Xia Si
DFI | Director of Finance/CFO | 56 | 31/03/93 |
Maolin Wang
CHM | Chairman | 59 | 31/12/00 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bao Guo Zhu
CHM | Chairman | 62 | 31/12/01 |
Qiu Sheng Tian
BRD | Director/Board Member | 68 | 14/10/19 |
Hua Min Huang
BRD | Director/Board Member | 53 | 31/05/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.42% | 4 M€ | -2.96% | ||
| 0.36% | 2 M€ | -16.59% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 38.98 | -1.32% | 8,895,020 |
| 25/04/24 | 39.5 | +3.54% | 12,179,720 |
| 24/04/24 | 38.15 | +2.42% | 6,501,306 |
| 23/04/24 | 37.25 | -0.72% | 5,739,900 |
| 22/04/24 | 37.52 | -0.87% | 5,352,829 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
20/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
38.98
CNY
Average target price
40.8
CNY
Spread / Average Target
+4.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.34% | 4.34B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 000513 Stock
